Abstract: The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation.

Abstract: The present invention relates to hygienic products such as sanitary pads and tampons, patient/adult diapers and baby diapers which are made antimicrobial. In the present invention, a mixture of glucopon, chlorhexidine gluconate and triclosan is obtained from the boron compounds called sodium borate, zinc borate, sodium perborate tetrahydrate, borax pentahydrate and disodium octaborate tetrahydrate; and this mixture provides antifungal, anticandidal, antibacterial and antiviral properties to the woven or non-woven textile products and hygienic products. Additionally, the said hygienic products are made hydrophilic by means of the invention.

Abstract: Disclosed in certain embodiments is a dosage form comprising a plurality of extruded particles comprising an adverse agent or antagonist and a layer disposed about the particles.

Abstract: Disclosed herein is a use of Fe3-?O4 nanoparticle in inhibiting the spore germination of Clostridium difficile. The Fe3-?O4 nanoparticle specifically targets the spores of Clostridium difficile spores by damaging and breaking the intact structure of the Clostridium difficile spores. Further, the Fe3-?O4 nanoparticle possesses superior sporicidal activity, as compared to other known bactericidal nanoparticles. Therefore, the Fe3-?O4 nanoparticle of the disclosure is useful as a bactericide or more specifically, a sporicide to treat Clostridium difficile infection for its superior sporicidal activity.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.

Abstract: Food processing equipment, food contact surfaces, and non-food contact surfaces are sanitized or disinfected using an acid-anionic surfactant solution that has efficacy in hard water, is non-corrosive, and is stable at elevated temperatures. The sanitizing/disinfecting solution is prepared as a highly concentrated liquid and diluted to end use concentrations prior to application to food processing equipment or food or non-food contact surfaces. Efficacy in hard water is important for sanitizers and disinfectants that are diluted by the end user using potentially hard water. Stability at elevated temperatures is important for long-term storage and transportation. The diluted sanitizing/disinfecting solution exhibits strong antimicrobial activity against gram positive and gram negative bacteria even when diluted in hard water. The sanitizing/disinfecting solution exhibits low toxicity to humans and the environment since it is prepared from low toxicity ingredients that are readily biodegradable.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: A hair care product comprising 100% plant derived, biodegradable solid granules that sustain beneficial essential oils or herbal extracts that emulsify in water to create an emulsified therapeutic solution is disclosed. The hair care product improves over existing liquids in that its solid granule form is completely plant derived and biodegradable and can sustain essential oils and antioxidants without the requirement of chemical preservatives, and can be packaged in eco-friendly water soluble film and compostable paper. It improves over existing solid forms in that it is a 100% water soluble granule that emulsifies easily in water to form an easy to use liquid product.

Abstract: The present invention relates to materials having therapeutic compositions releasably contained within the materials. The materials are configured to release therapeutic compositions at a desired rate. The present invention also relates to devices incorporating the materials.

Abstract: The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.

Abstract: This disclosure teaches phospholipid nanoparticle compositions of cannabinoids formed from phospholipids and simpler lipids in an unfired sequential process that encapsulate a high concentration of cannabinoids, and create standardized precision-metered dosage forms of cannabinoids; yielding an increase cannabinoid transport across hydrophobic mucosa; increase the bioavailability of the cannabinoid 2-fold to 8-fold, decrease the dose of cannabinoids 2-fold to 8-fold less than an amount of cannabinoids needed to illicit the same therapeutic effect compared to raw and non-encapsulated cannabinoids; where the nanoparticle dynamic structure reduces the adverse effects of cannabinoids; and enable safe more efficacious cannabinoid therapy.

Abstract: The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty. More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the site of intervention. The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12.

Abstract: The invention relates to a composition containing between 0.1 and 30 wt.-% copolyamide (COPA) and between 70 and 99.9 wt.-% of a medium acceptable for cosmetic, perfume and/or pharmaceutical use. In particular, the invention relates to a method for incorporating a copolyamide into a cosmetic, perfume and/or pharmaceutical medium. The invention also relates to the use of a copolyamide (COPA) for the production of a cosmetic, pharmaceutical or perfume product, said COPA being incorporated in the form of a composition in accordance with the invention.

Abstract: The present invention provides a system comprising: (i) a layer containing a nitrite; and (ii) a hydrogel that contains hydrogen ions; wherein the layer containing a nitrite and/or the hydrogel comprises a pharmaceutically active agent. The invention also provides the use of a system of the invention in medicine, and in the treatment of pain.

Abstract: The invention provides novel nanoscale delivery vehicles and composite nanoassemblies built from distinct nanoassembly units (e.g., block copolymer micelles and nanogels) with stoichiometric control. These intelligent composite nanoassemblies independently retain the key features of the nanoassembly units and greatly expand the potential functional features attainable based on the surface functionalization. The invention provides a novel approach to constructing nano-vehicles with controllable morphology based on combination of cooperative releasing mechanisms (e.g., redox sensitive nanogels and pH sensitive micelles). Two kinds of guests can be seperately and stably encapsulated in the composite nanocontainers, and then released sequentially under the stimulation of pH change and reduced glutathione.

Abstract: The present invention relates to compositions in the form of oil-in-water dispersions comprising a silicone oil having an average droplet diameter from about 30 microns to about 2000 microns and a polymeric thickening agent. These compositions are useful for stimulating collagen production in human patients and other mammals, and have applications for soft tissue augmentation for various medical and cosmetic procedures. The present invention also relates to methods for preparing these compositions and to methods for stimulating collagen production in human patients and other mammals in need thereof. In contrast to the prior art, the compositions and methods of the present invention are particularly useful for stimulating the production of high quality collagen that is uniform, smooth, long-lasting, and having good structural integrity.

Abstract: The present invention provides a process for preparing a particulate medicament that has greater homogeneity and a lower adhesion between the particles of the active ingredient and the carrier. The process comprises the steps of: (a) combining a pharmaceutically active ingredient in the form of an agglomerate of primary particles having an agglomerate particle size such that the agglomerate is capable of passing through a sieve having a mesh of 50-3000 .mu.m with a pharmaceutically acceptable particulate carrier, and (b) mixing the resultant material in a mixer to break up the agglomerate into primary particles dispersed in the pharmaceutically acceptable particulate carrier such that 90% or more of the pharmaceutically active ingredient exists as primary particles having a particle size of 50 .mu.m or less.

Abstract: Antiperspirant compositions that are suitable in particular for application with a roller applicator and contain water, at least one antiperspirant aluminum-zirconium-glycine complex and also L-valine, wherein the weight ratio of glycine to L-valine is in the range of about 20:1 to about 4:1, have a high antiperspirant efficacy and are tolerated very well on the skin at the same time.